DE60217835D1 - Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c - Google Patents
Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein cInfo
- Publication number
- DE60217835D1 DE60217835D1 DE60217835T DE60217835T DE60217835D1 DE 60217835 D1 DE60217835 D1 DE 60217835D1 DE 60217835 T DE60217835 T DE 60217835T DE 60217835 T DE60217835 T DE 60217835T DE 60217835 D1 DE60217835 D1 DE 60217835D1
- Authority
- DE
- Germany
- Prior art keywords
- glccer
- protein
- gb3cer
- methods
- risikofaktor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27210301P | 2001-02-28 | 2001-02-28 | |
US27804501P | 2001-03-22 | 2001-03-22 | |
PCT/US2002/006340 WO2002102325A2 (en) | 2001-02-28 | 2002-02-28 | Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60217835D1 true DE60217835D1 (en) | 2007-03-15 |
Family
ID=26955302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60217835T Expired - Fee Related DE60217835D1 (en) | 2001-02-28 | 2002-02-28 | Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c |
Country Status (6)
Country | Link |
---|---|
US (2) | US6756208B2 (de) |
EP (1) | EP1370570B1 (de) |
AT (1) | ATE352309T1 (de) |
AU (1) | AU2002326291A1 (de) |
DE (1) | DE60217835D1 (de) |
WO (1) | WO2002102325A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
EA200400548A1 (ru) | 2001-10-15 | 2005-06-30 | Чирон Корпорейшн | Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi) |
DE10206938A1 (de) * | 2002-02-19 | 2003-09-04 | Oce Printing Systems Gmbh | Verfahren und Einrichtung zum Drucken, wobei eine hydrophile Schicht erzeugt und diese strukturiert wird |
US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
US20040171522A1 (en) * | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
US20070184058A1 (en) * | 2003-02-27 | 2007-08-09 | Yaron Ilan | Glucocerebroside treatment of pulmonary or respiratory diseases or disorders |
US9717754B2 (en) * | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
CN101426520A (zh) * | 2004-03-17 | 2009-05-06 | 诺华疫苗和诊断公司 | 通过给予组织因子途径抑制剂(tfpi)治疗社区获得性重症肺炎 |
JP2008507561A (ja) * | 2004-07-23 | 2008-03-13 | ザ ユニバーシティ オブ ロチェスター | 活性化プロテインcによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害 |
EP1874334A4 (de) * | 2005-04-15 | 2011-03-30 | Vascular Biogenics Ltd | Zusammensetzungen mit von beta 2-glykoprotein i stammenden peptiden zur prävention und/oder behandlung von gefässerkrankungen |
AU2007222018A1 (en) | 2006-03-09 | 2007-09-13 | Alltech Associates, Inc. | Evaporative light scattering detector |
US20080194527A1 (en) * | 2007-02-14 | 2008-08-14 | Tcp Innovations Ltd | Compositions and combinations 2 |
US20090286740A1 (en) * | 2008-05-15 | 2009-11-19 | Fibrex Medical Research & Development Gmbh | Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
US20120148547A1 (en) * | 2009-09-01 | 2012-06-14 | Hadasit Medical Reasearch Services & Development Ltd. | Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders |
ES2768995T3 (es) * | 2009-11-17 | 2020-06-24 | Baylor Res Institute | 1-desoxigalactonojirimicina para el uso en el tratamiento de una enfermedad cardíaca |
US20110136858A1 (en) * | 2009-12-04 | 2011-06-09 | Grainger David J | Preferred Combination Therapy |
US20130196934A1 (en) * | 2010-01-21 | 2013-08-01 | Paul Bradley Addis | Composition for perinatal and neonatal stroke |
US20120178105A1 (en) * | 2011-01-10 | 2012-07-12 | Genzyme Corporation | Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich |
CN102798598A (zh) * | 2011-05-25 | 2012-11-28 | 兆科药业(合肥)有限公司 | 一种检测磷脂依赖性凝血因子x激活物酶活性的方法 |
HUE055562T2 (hu) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
CN104122396A (zh) * | 2013-04-23 | 2014-10-29 | 中国科学院上海生命科学研究院 | 维生素k依赖性蛋白s作为糖尿病标志物的应用 |
CN103308636B (zh) * | 2013-04-28 | 2014-04-09 | 山东信立泰药业有限公司 | 一种D-(+)-α-(2-噻吩乙胺基)-α-(2-氯苯基)乙酸甲酯或其盐的质量控制方法及其在氯吡格雷生产中的应用 |
US20170035791A1 (en) * | 2014-04-14 | 2017-02-09 | Natural Shield Israel 2016 Ltd | Combination of beta-glucosylceramide and polyethoxylated castor oil and other adjuvants for controling blood sugar levels, immunoprotection and hepatoprotection |
EP3145489A1 (de) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natürliche kombinierte hormonersatzformulierungen und therapien |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US11058750B2 (en) * | 2015-12-03 | 2021-07-13 | Mor Research Applications Ltd. | Compositions and methods for treatment of ocular diseases |
BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
CN108931595B (zh) * | 2018-06-20 | 2021-05-11 | 广东省测试分析研究所(中国广州分析测试中心) | 一种明胶型凝胶糖果中磷脂酰丝氨酸含量的测定方法 |
CN108836897A (zh) * | 2018-08-21 | 2018-11-20 | 湖南博隽生物医药有限公司 | 一种含有玫瑰精油的化妆品及其制备方法 |
EP3632427A1 (de) * | 2018-10-01 | 2020-04-08 | Mehdi Namdar | Neue mittel zur verwendung bei der behandlung von herzrhythmusstörungen |
CN109700998B (zh) * | 2019-02-25 | 2022-02-08 | 曾湘红 | 一种复方肌肤损伤再生修复剂及其制备方法 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
CN112375133A (zh) * | 2020-09-18 | 2021-02-19 | 江苏艾迪药业股份有限公司 | 亲和层析柱纯化凝血酶调节蛋白的方法 |
CN113243338A (zh) * | 2021-05-14 | 2021-08-13 | 福州大学 | 一种小鼠缺血性卒中模型的构建与评估方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4416872A (en) * | 1982-03-17 | 1983-11-22 | The United States Of America As Represented By The Secretary Of The Army | Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates |
US4766111A (en) * | 1985-10-31 | 1988-08-23 | Trustees Of Boston University | Lipids with plasmin inhibitory properties |
US5047354A (en) * | 1987-10-30 | 1991-09-10 | Foegh Marie L | Thromboxane B2 assay for coronary artery thrombosis |
JPH02270823A (ja) * | 1989-04-11 | 1990-11-05 | Ube Nitto Kasei Co Ltd | 抗血液凝固剤 |
DE4025330A1 (de) * | 1990-08-09 | 1992-02-13 | Basf Ag | Lipidderivate und verfahren zu deren herstellung |
FR2764511B1 (fr) * | 1997-06-13 | 2000-09-08 | Sanofi Sa | Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire |
AU750141B2 (en) * | 1997-12-30 | 2002-07-11 | A+ Science Invest Ab | Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications |
JP2002521435A (ja) * | 1998-07-27 | 2002-07-16 | ジョンズ・ホプキンス・ユニバーシティ | ラクトシルセラミドによって調節される病態を治療する方法 |
JP2002538226A (ja) | 1999-03-11 | 2002-11-12 | デュポン ファーマシューティカルズ カンパニー | Xa因子阻害剤およびアスピリン、組織プラスミノーゲンアクチベータ(TPA)、GPIIb/IIIa拮抗剤、低分子量ヘパリンまたはヘパリンの組合せ使用による血栓症の治療 |
-
2002
- 2002-02-28 US US10/086,943 patent/US6756208B2/en not_active Expired - Fee Related
- 2002-02-28 DE DE60217835T patent/DE60217835D1/de not_active Expired - Fee Related
- 2002-02-28 AT AT02760992T patent/ATE352309T1/de not_active IP Right Cessation
- 2002-02-28 WO PCT/US2002/006340 patent/WO2002102325A2/en active IP Right Grant
- 2002-02-28 EP EP02760992A patent/EP1370570B1/de not_active Expired - Lifetime
- 2002-02-28 AU AU2002326291A patent/AU2002326291A1/en not_active Abandoned
-
2003
- 2003-12-17 US US10/739,962 patent/US20040132688A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE352309T1 (de) | 2007-02-15 |
EP1370570B1 (de) | 2007-01-24 |
EP1370570A4 (de) | 2004-10-13 |
US20040132688A1 (en) | 2004-07-08 |
US6756208B2 (en) | 2004-06-29 |
WO2002102325A2 (en) | 2002-12-27 |
US20020177563A1 (en) | 2002-11-28 |
AU2002326291A1 (en) | 2003-01-02 |
WO2002102325A3 (en) | 2003-09-12 |
EP1370570A2 (de) | 2003-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60217835D1 (en) | Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c | |
Greengard et al. | Binding of coagulation factor XI to washed human platelets | |
Huntington | Molecular recognition mechanisms of thrombin | |
Koppelman et al. | Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII | |
van ‘t Veer et al. | An in vitro analysis of the combination of hemophilia A and factor VLEIDEN | |
Roberts et al. | A cell-based model of thrombin generation | |
Heeb et al. | Protein S binds to and inhibits factor Xa. | |
Giles et al. | The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits | |
Pratt et al. | Heparin binding to protein C inhibitor. | |
Griffin et al. | Deficiency of protein C in congenital thrombotic disease. | |
Furie et al. | Molecular and cellular biology of blood coagulation | |
Freyssinet et al. | The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex | |
ES2115679T3 (es) | Preparacion de reactivos de tiempo de protrombina a partir de factor de tejido humano recombinante y de fosfolipidos sinteticos y naturales purificados. | |
Oliver et al. | Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces | |
De Cristofaro et al. | Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib | |
Felez et al. | Binding of tissue plasminogen activator to human monocytes and monocytoid cells | |
Mumford et al. | A Tyr346→ Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII: C assay discrepancy | |
Lijnen et al. | Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma | |
Halvorsen et al. | Does Lp (a) lipoprotein inhibit the fibrinolytic system? | |
Wu et al. | Role of procoagulant lipids in human prothrombin activation. 1. Prothrombin activation by factor Xa in the absence of factor Va and in the absence and presence of membranes | |
Butenas et al. | Decryption of tissue factor | |
Lu et al. | Ile73Asn mutation in protein C introduces a new N-linked glycosylation site on the first EGF-domain of protein C and causes thrombosis | |
Barrow et al. | Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex. | |
Booyse et al. | Normal but not hypertriglyceridemic very low-density lipoprotein induces rapid release of tissue plasminogen activator from cultured human umbilical vein endothelial cells | |
Mikaelsson | The role of calcium in coagulation and anticoagulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |